• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.445 -0.305 (-11.09%)
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,452,809
Open 2.730
Bid (Size) 2.480 (300)
Ask (Size) 2.600 (200)
Prev. Close 2.750
Today's Range 2.440 - 2.730
52wk Range 1.660 - 4.330
Shares Outstanding 81,632,619
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
October 08, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy ↗
September 11, 2026
Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for... 
Via MarketBeat

Performance

52-Week Range 43.5% below 52-week high
2.445
1.6652W Low 4.3352W High
1 Week 17.7% below 1-week high
2.441W Low 2.971W High

Editas Medicine, Inc. - Common Stock (EDIT) traded between $1.66 and $4.33 over the past 52 weeks and last traded at $2.44, 43.5% below its 52-week high. Over the past week it ranged between $2.44 and $2.97.

Past 12 Months
-10.4%
-10.8%
-22.6%
-23.6%
+19.3%
-31.3%
1W -$0.29
1M -$0.30
3M -$0.72
6M -$0.76
YTD +$0.40
1Y -$1.12

EDIT was -31.3% over the past year, -23.6% over six months, +19.3% year to date, -10.4% in the last week.

12 Months vs Market
EDIT
-31.3%
DIA
+12.1%
SPY
+17.3%
QQQ
+23.5%
IWM
+13.2%

Over the past 12 months EDIT returned -31.3% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.5% and IWM (Russell 2000) +13.2%.

Volume & Liquidity 0.99× 3-mo avg
Today 2,452,809 3-mo avg 2.5M
1W
3.0M
1M
3.3M
3M
2.5M
6M
2.5M
YTD
2.2M
1Y
2.2M

EDIT most recently traded 2,452,809 shares against a 3-month average daily volume of 2.5M.

More News

Read More
News headline image
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
September 09, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 ↗
September 09, 2026
Via MarketBeat
Editas Medicine (NASDAQ:EDIT) Beats Q2 Estimates, but One-Time Revenue Boost Masks Underlying Momentum ↗
August 05, 2026
Via Chartmill
News headline image
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
September 08, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
September 01, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
August 31, 2026
Via Chartmill
News headline image
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
August 05, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
August 04, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗
May 31, 2026
Via The Motley Fool
News headline image
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
May 28, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
May 26, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Tuesday? ↗
May 26, 2026
Via Chartmill
News headline image
Editas Medicine Announces Proposed Public Offering
May 26, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
May 26, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
May 14, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces First Quarter 2026 Results and Business Updates
May 05, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
April 27, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
March 27, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Is Editas Medicine Going to $0? ↗
March 17, 2026
Via The Motley Fool
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
March 09, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
February 23, 2026
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas (EDIT) Q2 2024 Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings
News headline image
Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗
November 10, 2025
Via Chartmill

Frequently Asked Questions

Is Editas Medicine, Inc. - Common Stock publicly traded?
Yes, Editas Medicine, Inc. - Common Stock is publicly traded.
What exchange does Editas Medicine, Inc. - Common Stock trade on?
Editas Medicine, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Editas Medicine, Inc. - Common Stock?
The ticker symbol for Editas Medicine, Inc. - Common Stock is EDIT on the Nasdaq Stock Market
What is the current price of Editas Medicine, Inc. - Common Stock?
The current price of Editas Medicine, Inc. - Common Stock is 2.445
When was Editas Medicine, Inc. - Common Stock last traded?
The last trade of Editas Medicine, Inc. - Common Stock was at 10/13/26 04:00 PM ET
What is the market capitalization of Editas Medicine, Inc. - Common Stock?
The market capitalization of Editas Medicine, Inc. - Common Stock is 199.59M
How many shares of Editas Medicine, Inc. - Common Stock are outstanding?
Editas Medicine, Inc. - Common Stock has 200M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap